Journal Mobile Options
Table of Contents
Vol. 15, No. 4, 2003
Issue release date: April 2003
Cerebrovasc Dis 2003;15:235–243

Effects of Blood Pressure Lowering in the Acute Phase of Total Anterior Circulation Infarcts and Other Stroke Subtypes

Ahmed N. · Wahlgren N.G.
Stroke Research Unit, Department of Neurology, Karolinska Hospital, Stockholm, Sweden

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Lowering of blood pressure (BP) in the acute phase of stroke is reported both to worsen and to improve the outcome. To investigate whether heterogeneity exists between stroke subtypes in the response to BP lowering, we analysed data from the Intravenous Nimodipine West European Stroke Trial (INWEST). Methods: INWEST enrolled acute ischaemic stroke patients within 24 h (n = 295) to the following groups: placebo (n = 100), 1 mg/h nimodipine (n = 101) or 2 mg/h nimodipine (n = 94). Patients were retrospectively classified as total anterior circulation infarct (TACI) (i.e. hemiparesis + hemianopia + dysphasia) and non-TACI (exclusion of any one of these). Main outcome measures were neurological (Orgogozo) and functional (Barthel) scores at day 21. Results: 106 patients were labelled as TACI and 62 as non-TACI. No significant difference in BP was observed between the TACI and non-TACI subtypes at baseline, nor did the subtypes differ in BP course within the treatment groups. A higher proportion of non-TACI patients received postrandomisation antihypertensive agents in addition to the study drug compared with TACI patients (55% non-TACI vs. 26% TACI, p < 0.005). For TACI patients, there was no outcome difference between the placebo- and nimodipine-treated groups. For non-TACI patients, placebo had a significantly better neurological (p = 0.004) and functional (p = 0.04) outcome than the high-dose nimodipine group. In multivariate analysis for TACI patients, BP reduction and nimodipine treatment had no relation with outcome. Baseline stroke severity (p < 0.005) was the only significant predictor of the outcome at day 21. For non-TACI patients, diastolic BP (DBP) reduction (p = 0.03) and nimodipine treatment (p = 0.001) were related to neurological deterioration and nimodipine treatment (p = 0.01) to functional deterioration. Systolic BP reduction was associated with neurological (p < 0.005) and functional improvement (p = 0.01). Baseline stroke severity (p < 0.005) was related to both neurological and functional outcome. Conclusion: BP lowering and nimodipine treatment had no significant effect on outcome for TACI patients. For non-TACI patients, DBP lowering worsened the neurological outcome and high-dose nimodipine worsened both the neurological and functional outcome.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Wallace JD, Levy LL: Blood pressure after stroke. JAMA 1981;246:2177–2180.
  2. Britton M, Carlsson A, de Faire U: Blood pressure course in patients with acute stroke and matched controls. Stroke 1986;17:861–864.
  3. Jansen PA, Schulte BP, Poels EF, Gribnau FW: Course of blood pressure after cerebral infarction and transient ischemic attack. Clin Neurol Neurosurg 1987;89:243–246.
  4. Morfis L, Schwartz RS, Poulos R, Howes LG: Blood pressure changes in acute cerebral infarction and hemorrhage. Stroke 1997;28:1401–1405.
  5. Adams HP Jr, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JA, et al: Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994;25:1901–1914.
  6. The European Ad Hoc Consensus Group: Optimizing intensive care in stroke: A European perspective. Cerebrovasc Dis 1997;7:113–128.
  7. European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. Cerebrovasc Dis 2000;10:335–351.
  8. Hossman KA: Pathophysiology of cerebral infarction; in Vilken PJ, Bruyn GW, Klawans HL (eds): Handbook of Clinical Neurology. Amsterdam, Elsevier Science Publishers, 1988, vol 53, pp 107–153.
  9. Wahlgren NG, MacMahon DG, Keyser JD, Indredavik B, Ryman T for the INWEST Study Group: The Intravenous Nimodipine West European Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204–210.
  10. Ahmed N, Nasman P, Wahlgren NG: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke 2000;31:1250–1255.
  11. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
  12. Lindgren A, Norrving B, Rudling O, Johansson BB: Comparison of clinical and neuroradiological findings in first-ever stroke. A population-based study. Stroke 1994;25:1371–1377.
  13. Ahmed N, Wahlgren NG: High initial blood pressure after acute stroke is associated with poor functional outcome. J Intern Med 2001;249:467–473.
  14. Mathew NT, Rivera VM, Meyer JS, Charney JZ, Hartmann A: Double-blind evaluation of glycerol therapy in acute cerebral infarction. Lancet 1972;ii:1327–1329.
  15. Orgogozo JM, Dartigues JF: Clinical trials in acute brain infarction: The question of assessment criteria; in Battistini B, Fioriani P, Courbier R, Plum F, Fiesci C (eds): Acute Brain Ischaemia, Medical and Surgical Therapy. New York, Raven Press, 1986.
  16. Mahoney FI, Barthel DW: Functional evaluation: Barthel index. Md State Med J 1965;14:61–65.

    External Resources

  17. Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia – the ischemic penumbra. Stroke 1981;12:723–725.
  18. Warlow CP, Dennis MS, van Gijn J, Hankey GJ, Sandercock PAG, Bamford JM, Wardlaw J: Stroke: A Practical Guide to Management. Bath, Blackwell, Bath Press, 1996.
  19. Bamford J, Sandercock P, Jones L, Warlow C: The natural history of lacunar infarction: The Oxfordshire Community Stroke Project. Stroke 1987;18:545–551.
  20. Anderson CS, Taylor BV, Hankey GJ, Stewart-Wynne EG, Jamrozik KD: Validation of a clinical classification for subtypes of acute cerebral infarction. J Neurol Neurosurg Psychiatry 1994;57:1173–1179.
  21. Pinto AN, Melo TP, Lourenco ME, Leandro MJ, Brazio A, Carvalho L, Franco AS, Ferro JM: Can a clinical classification of stroke predict complications and treatments during hospitalization? Cerebrovasc Dis 1998;8:204–209.
  22. Wardlaw JM, Dennis MS, Lindley RI, Sellar RJ, Warlow CP: The validity of a simple clinical classification of acute ischaemic stroke. J Neurol 1996;243:274–279.
  23. Chamorro A, Vila N, Ascaso C, Elices E, Schonewille W, Blanc R: Blood pressure and functional recovery in acute ischaemic stroke. Stroke 1998;29:1850–1853.
  24. Wahlgren NG, Ranasinha KW, Rosolacci T, Franke CL, van Erven PM, Ashwood T, Claesson L: Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1,360 acute stroke patients. Stroke 1999;30:21–28.
  25. Wahlgren NG, Bornhov S, Bornhov S, Sharma A, Cederin B, Rosolacci T, Ashwood T, Claesson L for the CLASS Study Group: The Clomethiazole Acute Stroke Study (CLASS): Efficacy results in 545 patients classified as Total Anterior Circulation Syndrome (TACS). J Stroke Cerebrovasc Dis 1999;8:231–239.
  26. Broderick J, Brott T, Barsan W, Haley EC, Levy D, Marler J, Sheppard G, Blum C: Blood pressure during the first minutes of focal cerebral ischemia. Drugs Aging 1996;8:408–415.
  27. Powers WJ: Cerebral hemodynamics in ischemic cerebrovascular disease. Ann Neurol 1991;29:231–240.
  28. Powers WJ: Acute hypertension after stroke: The scientific basis for treatment decisions. Neurology 1993;43:461–467.
  29. Krieger DW, Demchuk AM, Kasner SE, Jauss M, Hantson L: Early clinical and radiological predictors of fatal brain swelling in ischemic stroke. Stroke 1999;30:287–292.
  30. Robinson TG, Dawson SL, Ahmed U, Manktelow B, Fotherby MD, Potter JF: Twenty-four-hour systolic blood pressure predicts long-term mortality following acute stroke. J Hypertens 2001;19:2127–2134.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50